7 essential questions to ask before choosing a pharmacovigilance platform

Executive summary

Selecting the right pharmacovigilance platform requires more than basic regulatory compliance. Sponsors should look for direct regulatory gateways, pre-submission validation, meaningful automation, test and sandbox environments, and a deployment model that scales without operational friction. cubeSAFETY meets all of these requirements through pre-validated global regulatory connections, real-time on-screen business rule checks, automated data ingestion and case creation, built-in test submissions, and a dedicated sandbox environment. Delivered as a cloud-based, out-of-the-box solution, cubeSAFETY reduces manual effort, accelerates readiness, and enables pharmacovigilance teams to maintain consistent, high-quality safety reporting across studies and regions.

The questions below help distinguish systems that merely meet minimum requirements from those that actively improve safety reporting efficiency and reliability.

 1. Do you offer readily available gateways to major regulatory agencies?

A modern drug safety system should provide pre-configured, direct gateways to major regulatory agencies such as the FDA, EMA, and PMDA. Direct connectivity enables timely, compliant submissions without relying on manual file transfers or third-party intermediaries.

Systems that require custom integrations or manual uploads introduce unnecessary operational risk. They increase the likelihood of errors, slow down submissions, and place additional burden on safety teams that are already working under tight regulatory timelines.

2. How does your system handle automated business rules and on-screen validation checks?

Effective safety reporting systems validate data against regulatory business rules before submission, not after. Built-in, real-time validation ensures errors are identified and corrected early, reducing the risk of rejections or follow-up queries from regulatory authorities.

When validation occurs only post-submission, teams are forced into reactive rework. Over time, this erodes efficiency and increases the cost of maintaining compliance.

3. Does your system provide direct feedback from regulatory agencies?

Regulatory acknowledgements and responses should be automatically received and visible within the safety system itself. Immediate access to agency feedback allows pharmacovigilance teams to resolve issues quickly and maintain reporting timelines.

Systems that rely on manual tracking across emails or external portals limit visibility and create avoidable delays, particularly when managing multiple studies or regions.

4. Can I send test files to ensure successful configuration before live reporting?

A reliable pharmacovigilance solution should support test submissions to regulatory agencies before going live. Testing confirms that data mappings, configurations, and integrations are functioning correctly before real deadlines are at stake.

Without the ability to send test files, teams often discover configuration issues only after live submissions have begun, when the impact is far more costly and disruptive.

5. What level of automation does the system include?

Automation should reduce manual data entry across safety case creation, validation, and submission workflows. Automated imports, pre-populated fields, and rule-driven consistency improve data quality while freeing safety teams to focus on oversight and signal management.

Systems that rely heavily on manual input may appear flexible at first, but they become increasingly difficult to scale as volumes grow and regulatory expectations increase.

 6. What does your implementation process look like?

Implementation should be fast, predictable, and require minimal ongoing IT effort. Cloud-based deployment models reduce complexity and allow teams to reach compliance readiness more quickly.

Lengthy implementations that depend on extensive customisation often delay go-live timelines and increase long-term maintenance costs, diverting attention away from core safety activities.

7. Is there a sandbox or test environment available?

A dedicated sandbox environment is essential for testing configurations and training users without impacting live data. It allows teams to validate workflows, rehearse submissions, and build confidence before moving into production.

Without a sandbox, organisations are forced to test changes directly in live environments, increasing the risk of disruption and reporting errors.

How cubeSAFETY stands out

Selecting a pharmacovigilance solution is not just about meeting regulatory requirements – it’s about enabling sustainable, efficient safety operations. cubeSAFETY is designed to simplify safety reporting while supporting global compliance at scale.

Regulatory compliance made simple

• Pre-validated gateways for submissions to FDA, EMA, PMDA, MFDS, and CDE

• Automated, on-screen validation to prevent errors before submission

• Real-time regulatory feedback displayed directly within the platform

Advanced automation to reduce manual work

• Auto-populated fields and bulk data imports

• Configurable business rules to enforce consistency and compliance

• End-to-end visibility of submission status and agency responses

Seamless implementation and usability

• Cloud-based deployment with minimal IT burden

• Dedicated sandbox environment for testing and training

• Scalable architecture that grows with your pharmacovigilance needs

Unlike traditional systems that rely on manual uploads or extensive customisation, cubeSAFETY delivers a fully integrated, out-of-the-box drug safety solution built for modern pharmacovigilance teams.

Looking for a simpler, more reliable approach to safety reporting?

Contact CRScube to learn how cubeSAFETY can support your pharmacovigilance operations.